Literature DB >> 32851584

The Administration Matrix Modifies the Beneficial Properties of a Probiotic Mix of Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus acidophilus LA-5.

Gréta Pápai1,2, Edgar Torres-Maravilla3, Florian Chain3, Éva Varga-Visi1, Otília Antal2, Zoltán Naár2, Luis G Bermúdez-Humarán3, Philippe Langella3, Rebeca Martín4.   

Abstract

Consumption of dairy products is one of the most natural ways to introduce probiotics. However, the beneficial effects of the probiotics might depend on the administration form. The aim of this study was to investigate the beneficial properties of two probiotic strains: Bifidobacterium animalis subsp. lactis (BB-12) and Lactobacillus acidophilus (LA-5) in different administration forms (capsules and yogurt). First, in vitro resistance to gastrointestinal condition, surface properties, and immunomodulation capacities were determined. Then, the anti-inflammatory properties of the probiotic strains administrated on yogurt or capsules were tested in a dinitrobenzene sulfonic acid (DNBS)-induced colitis mouse model. The survival rates of BB-12 and LA-5 strains to gastrointestinal conditions were slightly higher when yogurt was used as carrier. They showed most affinity to hexane (no-polar basic solvent) than ethyl-acetate (polar basic solvent). BB-12 showed the higher binding capacity to HT-29, Caco-2, and mucin. Both probiotic candidates suppress the secretion of IL-8 secretion by HT-29-TNF-α stimulated cells. Finally, administration of BB-12 and LA-5 strains improve colitis in mice. They protect against weight loss, inflammation, and hyperpermeability induced by DNBS. However, these anti-inflammatory effects were limited when mice were treated with the probiotic strain on a yogurt matrix. Overall results indicate that BB-12 and LA-5 positive properties are compromised depending on the matrix. Consequently, the selection of an appropriate matrix is an important criterion to conserve the positive benefits of these probiotic strains.

Entities:  

Keywords:  Anti-inflammatory properties; Food matrix; Probiotics; Starter cultures; Yogurt

Mesh:

Substances:

Year:  2021        PMID: 32851584     DOI: 10.1007/s12602-020-09702-2

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  21 in total

1.  A differential medium for lactic acid-producing bacteria in a mixed culture.

Authors:  H M Lee; Y Lee
Journal:  Lett Appl Microbiol       Date:  2008-04-25       Impact factor: 2.858

2.  Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic.

Authors:  Colin Hill; Francisco Guarner; Gregor Reid; Glenn R Gibson; Daniel J Merenstein; Bruno Pot; Lorenzo Morelli; Roberto Berni Canani; Harry J Flint; Seppo Salminen; Philip C Calder; Mary Ellen Sanders
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-06-10       Impact factor: 46.802

3.  Yogurt inhibits intestinal barrier dysfunction in Caco-2 cells by increasing tight junctions.

Authors:  Kelley K Putt; Ruisong Pei; Heather M White; Bradley W Bolling
Journal:  Food Funct       Date:  2017-01-25       Impact factor: 5.396

4.  Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats.

Authors:  Pedro A Ruiz; Micha Hoffmann; Silke Szcesny; Michael Blaut; Dirk Haller
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

5.  Low-fat yogurt alleviates the pro-inflammatory cytokine IL-1β-induced intestinal epithelial barrier dysfunction.

Authors:  Zhengyuan Zhai; Jiaojiao Wang; Baozhu Huang; Sheng Yin
Journal:  J Dairy Sci       Date:  2018-12-20       Impact factor: 4.034

6.  Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial.

Authors:  Bojana Bogovič Matijašić; Tanja Obermajer; Luka Lipoglavšek; Tjaša Sernel; Igor Locatelli; Mitja Kos; Alenka Šmid; Irena Rogelj
Journal:  J Dairy Sci       Date:  2016-05-04       Impact factor: 4.034

7.  Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy.

Authors:  Bor-Shyang Sheu; Hsiu-Chi Cheng; Ai-Wen Kao; Shan-Tair Wang; Yao-Jong Yang; Hsiao-Bai Yang; Jiunn-Jong Wu
Journal:  Am J Clin Nutr       Date:  2006-04       Impact factor: 7.045

8.  Attenuation of Colitis by Lactobacillus casei BL23 Is Dependent on the Dairy Delivery Matrix.

Authors:  Bokyung Lee; Xiaochen Yin; Stephen M Griffey; Maria L Marco
Journal:  Appl Environ Microbiol       Date:  2015-07-10       Impact factor: 4.792

9.  Identification of one novel candidate probiotic Lactobacillus plantarum strain active against influenza virus infection in mice by a large-scale screening.

Authors:  Noura Kechaou; Florian Chain; Jean-Jacques Gratadoux; Sébastien Blugeon; Nicolas Bertho; Christophe Chevalier; Ronan Le Goffic; Stéphanie Courau; Pascal Molimard; Jean Marc Chatel; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  Appl Environ Microbiol       Date:  2012-12-21       Impact factor: 4.792

10.  Identification and characterisation of an iron-responsive candidate probiotic.

Authors:  Jennifer R Bailey; Christopher S J Probert; Tristan A Cogan
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

View more
  1 in total

1.  Oral supplementation with selected Lactobacillus acidophilus triggers IL-17-dependent innate defense response, activation of innate lymphoid cells type 3 and improves colitis.

Authors:  Jiří Hrdý; Aurélie Couturier-Maillard; Denise Boutillier; Carmen Lapadatescu; Philippe Blanc; Jan Procházka; Bruno Pot; Bernhard Ryffel; Corinne Grangette; Mathias Chamaillard
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.